{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:00:22Z","timestamp":1780707622628,"version":"3.54.1"},"reference-count":0,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:p>Introduction and Objective: Lean mass loss during pharmacologic weight reduction remains a key limitation of current obesity therapies. BG-104 is a multi-pathway therapeutic integrating GLP-1, GIP, and human growth hormone (hGH) receptor agonism with Activin Type II Receptor (ActRII) targeting to promote adiposity reduction while preserving skeletal muscle.<\/jats:p>\n                  <jats:p>Methods: Metabolic and body composition effects were evaluated in aged diet-induced obese mice maintained on a high-fat diet for 22-weeks and treated with BG-104 every four days (Q4D), with vehicle and tirzepatide (Q2D and Q4D).<\/jats:p>\n                  <jats:p>Results: BG-104 produced body weight reduction comparable to tirzepatide, while body composition analysis demonstrated robust fat mass reduction with superior preservation of lean mass. Notably, ~99.5% of total weight loss was attributable to fat mass, indicating highly selective adiposity reduction with minimal lean mass decline.<\/jats:p>\n                  <jats:p>Conclusion: These findings suggest that multi-pathway targeting of incretin and anabolic signaling may improve the quality of weight loss and represents a differentiated metabolic therapeutic approach with potential relevance for obesity and sarcopenic obesity.<\/jats:p>\n                  <jats:p\/>\n                  <jats:sec>\n                    <jats:title>Disclosure<\/jats:title>\n                    <jats:p>Y. Jeon: None. Y. Seo: None. R. Sung: None. Y. Sung: None.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db26-3075-lb","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:11:47Z","timestamp":1780704707000},"update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["3075-LB: A Trispecific GLP-1\/GIP\/hGH Receptor Agonist Targeting Activin Type II Receptor Drives Selective Fat Mass Reduction"],"prefix":"10.2337","volume":"75","author":[{"given":"YOUNGJAE","family":"JEON","sequence":"first","affiliation":[{"name":"Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YONG-BOK","family":"SEO","sequence":"additional","affiliation":[{"name":"Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROSANNA","family":"SUNG","sequence":"additional","affiliation":[{"name":"Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOUNG CHUL","family":"SUNG","sequence":"additional","affiliation":[{"name":"Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/3075-LB\/168742\/3075-LB-A-Trispecific-GLP-1-GIP-hGH-Receptor","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/3075-LB\/168742\/3075-LB-A-Trispecific-GLP-1-GIP-hGH-Receptor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:11:47Z","timestamp":1780704707000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/3075-LB\/168742\/3075-LB-A-Trispecific-GLP-1-GIP-hGH-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":0,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.2337\/db26-3075-lb","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"3075-LB"}}